Literature DB >> 23990980

Risk factors for acute endophthalmitis following cataract surgery: a systematic review and meta-analysis.

He Cao1, Lu Zhang, Liping Li, Singkai Lo.   

Abstract

BACKGROUND: Acute endophthalmitis is one of the most serious complications of cataract surgery and often results in severe visual impairment. Several risk factors for acute postoperative endophthalmitis (POE) following cataract surgery have been reported but the level of evidence and strength of association is varied. The purpose of this study was to critically appraise published reports on and to summarize clinical risk factors associated with acute POE which could be easily assessed by ophthalmologists for the introduction and implementation of preventive measure.
METHODS: A systematic review and meta-analysis of observational studies was performed. Six databases were searched with no limits on the year or language of publication. Study-specific odds ratios (Ors) or relative risk (RR) of each risk factor were pooled using a random effect model.
RESULTS: A total of 6 686 169 participants with 8 963 endophthalmitis in 42 studies were analyzed. Of the nine risk factors identified in our systematic review and meta-analysis, extra- or intracapsular cataract extraction, a clear corneal incision, without intracameral cefazolin (1 mg in 0.1 ml solution), without intracameral cefuroxime (1 mg in 0.1 ml solution), post capsular rupture, silicone intraocular lenses and intraoperative complications were found strongly associated with acute endophthalmitis. Other significant factors with a lower strength of association (risk estimates generally 1.5 or less) were male gender and old age (85 years and older).
CONCLUSIONS: Our study provides summary data on the risk factors for acute POE. Identifying patients at high risk of this sight-threatening eye disease is important from both the public health and clinical perspectives as this would facilitate detection of disease before the onset of irreversible visual loss enabling earlier intervention.

Entities:  

Mesh:

Year:  2013        PMID: 23990980      PMCID: PMC3753305          DOI: 10.1371/journal.pone.0071731

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

The World Health Organization's Prevention of Blindness and Visual Impairment makes the global estimate that the number of people of all ages visually impaired is estimated to be 285 million, of whom 39 million are blind in 2010. The major causes of visual impairment are uncorrected refractive errors (43%) and cataract (33%) ; cataracts remain the leading cause of blindness (51%) [1]. Cataract surgery is becoming more prevalent in the elderly as the life expectancy of the population increases. There has been a dramatic shift in surgical practice during the last 30 years with small-incision phacoemulsification being the predominant method of intervention used since 1990. Although cataract surgery is highly effective and relatively safe, owing to the enormous numbers, even uncommon surgical complications could potentially harm many patients. Endophthalmitis is one of the most serious complications of cataract surgery and often results in severe visual impairment [2]. Nationwide surveys and large case series of postcataract endophthalmitis (POE) in different countries estimated that the incidence for endophthalmitis ranged from 0.012% to 1.3% since 2000, in part because of differences in study design, time, and region [3, 17 ∼ 32]. Earlier literatures stratified the results over time and noted decreasing endophthalmitis rates, from 0.327% in the 1970s to 0.158% in the 1980s and 0.087% in the 1990s [4], [43], [57]. The optimal means to prevent POE remains controversial because conducting the large studies required to investigate an uncommon problem is difficult. While preoperative preparation with 5% povidone-iodine solution dropped into the conjunctival sac is the best established method of chemoprophylaxis based on the current clinical evidence, the benefit of other forms of perioperative factors remains uncertain [5], [6], [8], [24], [28], [36]. Several extensive reviews have been written regarding this topic despite the variable evidence and strength of association [6∼11]. A recent meta-analysis found a spike in endophthalmitis rates up to 0.265% during 2000–2003, which might be attributable to the popularization of sutureless clear corneal incisions [4]. Two other studies reported reduced rates of postoperative endophthalmitis among surgeries in the mid- 2000s compared to those performed in the late 1990s, suggesting sutureless incisions may not be the culprit [22], [67]. Herein, we seek to review the most up-to-date evidence and provide our opinion with regard to methods of endophthalmitis prophylaxis for cataract surgery. This meta-analysis identified the patient-related and surgery-related factors that affect the risk for acute POE following cataract.

Materials and Methods

Search Strategy

We conducted a systematic review of six databases, including PubMed (1950 to February 1, 2013), EMBASE (1966 to February 1, 2013) , Web of Science (1900 to February 1, 2013), Cochrane library (including the Cochrane Central Register of Controlled Trials, 1800 to February 1, 2013), abstracts from the Association for Research in Vision and Ophthalmology (January 1962 to February 1, 2013), and the National Institutes of Health Clinical Trial Databases [10] (up to February 1, 2013). These databases were searched systematically using the terms [(endophthalmitis) and (cataract surgery or cataract extraction or cataract or intracapsular cataract extraction or extracapsular cataract extraction or phacoemulsification) and (risk factors or association)]. The search strategy used both keywords and Medical Subject Headings (MeSH) terms. There were no limits placed on the year of publication. All potentially relevant non-English publications were to be translated into English for further assessment. References identified from bibliographies of pertinent articles or books also were retrieved. We followed the criteria used in the Endophthalmitis Vitrectomy Study (EVS) [29], not excluding any presumed acute endophthalmitis after cataract surgery (i.e., including suspected and/or confirmed cases by positive culture), because it would allow for the inclusion of more studies in order to generate more power for analyzing this relatively rare complication. Retrieved studies were imported into Refworks (version 1.0; Refworks, Bethesda, MD). Duplicate articles appeared twice or more, whether in the same or different databases were deleted. Data extraction and evaluation of study quality were performed independently by two reviewers; any disagreements were resolved by discussion with the senior investigators. The bibliographies of the full text articles that were reviewed were searched for relevant references. Full-text articles were then obtained based on the initial screening of abstracts and the data extraction form was completed. The full texts of the remaining studies were then read to determine whether they met our inclusion criteria. In addition, the reference lists from all identified studies were examined. Potential 45 risk factors for endophthalmitis following cataract surgery were identified in the initial review (Table 1).
Table 1

Potential 45 risk factors for endophthalmitis following cataract surgery were identified in the initial review.

Preoperative risk factors ( n = 13 )
• Male gender*
• Older individuals ( ≥85 years ) *
• Black race
• Native Americans
• Diabetes mellitus
• Recent tamsulosin exposure ( <14 days before surgery)
• Same day surgery
• Inpatient surgery
• Outpatient surgery
• Dedicated ophthalmic theatre
• Private hospital
• Preoperative topical antibiotics
• Residence inside of city
Intra-operative risk factors ( n = 26 )
• Surgeons with low annual volume ( 1∼50 surgeries )
• Surgeons with less experience ( 1∼10years )
• Consultant grade surgeon
• Surgeries performed in 2003
• Face masks not worn in theatre
• Skin disinfection type ( 5% povidone-iodine )
• Conjunctival disinfection type ( without povidone-iodine )
• Topical anesthesia
• Region of cataract surgery: region 6 and 9
• Surgery longer than 45 minutes
• Without intracameral cefazolin*
• Without intracameral cefuroxime*
• Without fourth-generation fluoroquinolones
• Without intracameral vancomycin
• Without subconjunctival antibiotics at the end of surgery*
• Posterior capsular rupture*
• Intraoperative complications*
• A clear corneal incision*
• Silicon based IOL*
• Polymethyl methacrylate based IOL
• Foldable IOL
• Communication between the anterior and vitreous
• Nonadministration of subconjunctival antibiotics
• Extra- or intracapsular cataract extraction*
• Other eye procedures during the same admission ( vitreoretinal procedure, lacrimal/eyelid procedures or adjunctive MMC for inferior filtration)
• Phacoemulsification
Postoperative risk factors ( n =  6 )
• Wound leak on the first postoperative day
• Topical antibiotic started the day after surgery
• Use of ciprofloxacin rather than ofloxacin topically after surgery
• Not patching after surgery
• Not placing a collagen shield soaked in antibiotic
• Length of stay ( ≥8 days )

*Results were put into meta-analysis.

*Results were put into meta-analysis.

Inclusion and Exclusion Criteria

Studies were included if they (i) reported cataract surgery as covariate, (ii) had exogenous acute endophthalmitis as the outcome measure, including the suspected and/or confirmed cases by positive culture, If a positive culture of a vitreous sample was obtained, we defined the case as a proven acute endophthalmitis. In all proven and unproven cases, the patients had swollen lids, pain and an opaque vitreous. (iii) reported a measure of the association either as odds ratio (OR) or relative risk (RR) with 95% confidence interval (CI), or allowed for the calculation of it from the raw data presented in the article, and (iv) the study examined human cases. We excluded (i) studies involving posttraumatic endophthalmitis or endogenous endophthalmitis, (ii) studies without a clear-cut definition of cataract surgery or detailed description of acute endophthalmitis assessment, (iii) samples including cases of TASS (toxic anterior segment syndrome), (iv) studies with underwent secondary lens implantation, intraocular lenses (IOLs) exchange, or cataract surgery combined with filtering procedures or corneal transplantation were excluded (Figure 1).
Figure 1

Flow diagram showing the selection process for inclusion of studies in the meta-analysis.

CI  =  confidence interval.

Flow diagram showing the selection process for inclusion of studies in the meta-analysis.

CI  =  confidence interval.

Data Extraction and Quality Assessment

For each study, the following characteristics were extracted: (i) last name of first author, (ii) year of publication, (iii) study design and follow-up, (iv) location of the population, (v) date of the study, (vi) sample size and age range of subjects in the analysis, (vii) number of endophthalmitis, (viii) definition of cataract surgery, (ix) estimates of odds ratios (ORs), relative risks (RR), or the primary data required to calculate these ratios, (x) quality criteria. The clinical quality criteria was assessed with the Levels of Evidence offered by Oxford Centre for Evidence-based Medicine in March 2009 [12] (Table 2).
Table 2

Summary of the included studies evaluating risk factors and the association with acute endophthalmitis following cataract surgery.

Authors, Year [Ref]Data SourceStudy DesignPresentation interval(days)CountryDatePopulation Sample size, age[yrs]Total Number of endophthalmitis (incidence rate%)Definition of the endophthalmitisType of confirmed pathogen (n)Risk factors (RR/OR) & Classification of cataract surgeryQuality Criteria?
Das T, 2012 [16] EDCC15±12India1993∼ 199846 095 42∼8162(0.13%)Suspected (62) Confirmed (36)S. Epidermidis(16); P. Aeruginosa(5); GPC (other)# (8) Others(7)OR: Ambulatory patients care (3.63) Residence location within city(2.27)ECCE PhacoemulsificationB
Keay L, 2012 [17] ? EDRONRUSA2003∼ 20043 280 966 NA4 006 (0.012%)Suspected (4006)NRRR: Male (1.23) Older individuals(≥85)(1.53) Black (1.17) Native Americans (1.72) Surgeons with low annual volume (3.8) Surgeons with less experience (1.41) surgeries performed in 2003 (1.2)NAB
Romero-Aroca P, 2012 [18] ? EDPO5.37±2.33Spain1996∼ 200925 001 53∼8983 (3.32%)Suspected (83) Confirmed (55)NRRR: Without intracameral cefazolin (11.45)PhacoemulsificationA
Tan CS, 2012 [19] ? EDCohNRSingapore11 years50 177 NR21(0.042%)Suspected(21)NROR: Without intracameral cefazolin (13.6) Age(1.05) Male gender(2.96)NAB
García-Sáenz MC 2010 [20] ? EDCSNRSpain1999∼ 200915 173 NR43(0.28%)Suspected (43)NRRR: Without intracameral cefuroxime (8.57)NAA
Anijeet DR, 2010 [21] EDRO1∼14UK1998∼ 200816 606 NR14(0.078%)Suspected(14) Confirmed(6)GPC#(1); P. Streptococcus(3) P. aeruginosa (1); Nil(1)RR: without intracameral vancomycin (38)NAB
Freeman EE 2010 [22] ? EDRO<90Canada1996∼ 2005490 690 NR754(0.15%)Suspected(754)NROR:Older individuals(≥85)(1.34) Male gender(1.44) later year of surgery (0.94) Region of surgery 6 and 9(6∼9)NAB
Lloyd JC, 2009 [23] EDRO1∼35Canada2006∼ 200513 931 NR5(0.036%)Suspected(5) Confirmed(4)Staphylococcus(2); Streptococcus(1);P.acnes(1);OR:Without fourth-generation fluoroquinolones perioperatively(6.3)PhacoemulsificationB
Al-Mezaine HS, 2009 [25] ? EDRONRArabia1029 412 NR20(0.068%)Suspected(20) Confirmed(18)Staphylococcus (7); Streptococcus(7); P.acnes(1); others(3)OR:clear corneal incision(1.73)ECCE PhacoemulsificationB
Garat M, 2009 [26] ? EDCCNRSpain2002∼ 200718 579 NR31(0.167%)Suspected(27) Confirmed(4)NRRR: Without intracameral cefazolin(8.89)PhacoemulsificationB
Hatch WV, 2009 [27] ? EDCohNRCanada2002∼ 2006442 177 NR617(0.14%)Suspected(617)NROR: Male gender(1.4) Capsular rupture(9.56) Older individuals(1.24)ECCE PhacoemulsificationA
Pleyer U, 2008 [28] ? EDCohNREuropeNR16211 NR29(0.179%)Suspected(29) Confirmed(20)NRRR: Without intracameral cefuroxime(4.92) Clear corneal incision(5.88) Silicon based IOL(3.13) Intraoperative complications(4.95)PhacoemulsificationA
Garcia-Arumi J, 2007 [30] ? EDCC<30Spain2002∼ 20035 011 NR27(0.539%)NRNROR: Topical anesthesia(11.8) Surgery longer than 45minutes(7.2)NAA
Endophthalmitis Study Group, 2007 [31] ? EDCohNRAustria, Belgium, Germany, Italy, etc.NR16 603 NR29(0.175%)Suspected(29) Confirmed(20)NROR: Without intracameral cefuroxime (4.92) Clear corneal incision(5.88) Silicone IOL(3.13) Surgical complications(4.95) Male gender(2.70)ECCE PhacoemulsificationA
Lundström M 2007 [32] ? EDPONRSweden2002∼ 2004225 471 NR109(0.048%)Suspected(109)NRRR: Communication between the anterior and vitreous Older individuals (≥85) Without intracameral cefuroximeECCE PhacoemulsificationA
Ng JQ, 2007 [33] ? WCCNRAustralia1980∼ 20001 025 NR205(NA)Suspected (205)NRRR: Same day surgery (2.27) Posterior capsule breach(13.57) Sub-conjunctival injection(0.46)ECCE PhacoemulsificationB
Kamalarajah S, 2006 [34] ? EDCCNRUK1999∼ 2000659 (73.5–75)214(NA)Suspected (214)NROR: Inpatient surgery(2.88) Dedicated center(2.76) Face masks not worn(3.34) Posterior capsule tear(3.82) Without subconjunctival antibiotics (6.85)ECCE PhacoemulsificationA
Barry P, 2006 [35] ? EDCohNRAustria, Belgium, Germany, Italy, etc.2003∼ 200613 698 NR28(0.2%)Suspected (28)NROR: Without intracameral cefuroxime (4.59)PhacoemulsificationA
Wu PC, 2006 [36] EDCCNRTaiwan1992∼ 200010 614 NR12(0.113%)Suspected (12)NROR: skin preparation with 5% povidone-iodine(10.9) without 5% povidone-iodine conjunctival disinfection(5.6)ECCEB
Wejde G, 2005 [37] ? EDCCNRSweden1994∼ 200044 986 NR60(0.133%)Suspected(60)NRRR: without intracameral cefuroxime(5.7) ECCE/ICCE(2.1) silicone lens((3.4)ECCE PhacoemulsificationB
Lalitha P, 2005 [38] ? EDRONRIndia2002∼ 200336 072 NR19(0.053%)Suspected(10) Confirmed(9)NRRR: posterior capsular rent(6.57) ECCE(4.9) older individuals(6.0)ECCE PhacoemulsificationB
West ES, 2005 [39] ? EDRONRUSA1994∼ 2001477 627 NR1 026(0.215%)Suspected(10) Confirmed(9)NRRR: surgeries before 1998(1.44) old individuals(90)(1.83) black race(1.30)ECCE PhacoemulsificationA
Wallin T, 2005 [40] ? EDCohNRUSA1996∼ 20021552 NR27(1.7%)Suspected(27)NRRR: Wound leak(44) Capsular complication(17.2) Topical antibiotic after surgery(13.7) With ciprofloxacin (5.3) Without patching (7.1) Without collagen shield (2.7)ECCE PhacoemulsificationB
Wejde G, 2005 [41] ? EDPONRSweden1999∼ 2001188 151 NR109(0.0595%)Suspected (91) Confirmed (21)GPB# RR: Without intracameral cefuroxime (3.649) ECCE/ICCE (1.7)ECCE PhacoemulsificationA
Li J, 2004 [42] ? WPONRAustralia1980∼ 2000117 083 NR210(0.179%)Suspected (210)NROR: Male 0.89(0.67–1.19) Older individuals(>80)1.50(1.13–1.99) Length of stay(+8days) (2.08) Private hospital (2.38) Length of study (>8days)(2.08) With vitreoretinal procedure (2.71) Lacrimal/eyelid procedures (23.5)ECCE ICCE Phacoemulsification other cataract extraction/ lens-related proceduresA
Wong TY, 2004 [43] ? EDPONRSingapore1996∼ 200144 803 NR34(0.076%)Suspected (34) Confirmed (21)RR:Phacoemulsification (3.1) Posterior capsule rupture (8.0)ECCE PhacoemulsificationA
Wong TY, 2004 [44] ? EDCC54∼80Singapore Chinese, Malay,etc.1996∼ 2001136 NR34(NA)Suspected (34) Confirmed (21)Staphylococcus (13) Streptococci (1); P.aeroginosa(1) Others(6)OR: Silicone IOL (5.1) Posterior capsular rupture (20.9)ECCE PhacoemulsificationB
Cooper BA, 2003 [45] ? EDCCNRUSA1997∼ 2000409 NR38(NA)Confirmed(38)NROR: Clear corneal incision (3.36)ECCE PhacoemulsificationB
E Mayer, 2003 [46] ? EDRONRUK1991∼ 200118 191 (43–89)30(0.16%)Suspected (30) Confirmed (26)Staphylococcus (9) P. Streptococcus (2) P.aeruginosa (1) Others(14)RR: ECCE (4.37) Folded IOL (43.8) Capsular rupture (2.06)ECCE PhacoemulsificationB
Ellis MF, 2003 [47] ? EDRONRAustralia1997∼ 2001633 NR5(0.78%)Confirmed (5)S. epidermidis (5)OR: Topical anesthesia (7.63)PhacoemulsificationB
Nagaki Y, 2003 [48] ? EDPONRJapan1998∼ 200111595 NR16(0.14%)Suspected (16) Confirmed (13)NRRR: Clear corneal incision (5.61)PhacoemulsificationA
Kalpadakis P, 2002 [49] ? EDRONRGreece1998∼ 20012 446 NR20(0.82%)Suspected (20)NRRR: ECCE (1.99)ECCE PhacoemulsificationA
Montan P, 2002 [50] ? EDPONRSweden199854 666 NR58(0.106%)Suspected (58) Confirmed (41)CNS #(15) Streptococci (12) S. aureus(4)OR: PMMA (2.03) Silicon (1.93) Hydrogel (2.89)Phaco + PC IOL ECCE + PC IOL Phaco/ECCE + AC IOLA
Lertsumitkul S, 2001[51] ? WCCNRAustralia1996∼ 199897 NR31(NA)Suspected (31) Confirmed (20)S. Epidermidis(9) S. aureus(5) Streptococcus(2)OR: Surgical complications (6.34) Clear corneal temporal incision (3.52)ECCE Phacoemulsification Penetrating keratoplastyB
Colleaux KM, 2000 [52] EDRONRSask1994∼ 199813 886 NR25 (0.18%)Suspected (25)NROR: without subconjunctival antibiotic injections (16.23)PhacoemulsificationB
Swaddiwudhipong W, 2000 [53] ? EDRONRThailand1997∼ 1998329 NR31(9.4%)Suspected (31)NRRR: ECCE (0.47)Phacoemulsification145 ECCE165 secondary IOL implantationB
Schmitz S, 1999 [54] EDCSNRGermany1996340 633 NR267 (0.148%)NRNROR: preoperative topical antibiotics (2.38) outpatient surgeries (2.0)NAA
Bainbridge JW, 1998 [55] ? EDRO12∼101United KingdomNA772 NR7(0.91%)Suspected (7) Confirmed(5)CNS# (3) S. aureus(1)RR: Silicone IOL (20.73)PhacoemulsificationB
Norregaard JC, 1997 [56] ? EDRONRDenmark1985∼ 198719 246 NR61(0.317%)Suspected (61)NROR: Old individuals≥90 (3.62) Male gender (1.93) ICCE (2.22) Capsular rupture (4.86)ECCE ± IOL ICCE ± IOLB
Javitt JC, 1991 [57] ? EDRONRUSA1984324 032 NR439(0.135%)Suspected(439)NROR: Capsular rupture (4.56) Male gender (1.23)ICCE 99971 ECCE 195587 Phacoemulsification 28474B
Authors, Year [Ref]Data SourceStudy DesignPresentation interval(days)CountryDatePopulation Sample size, age[yrs]Total Number of endophthalmitis (incidence rate%)Definition of the endophthalmitisType of confirmed pathogen (n)Risk factors (RR/OR) & Classification of cataract surgeryQuality Criteria?
Das T, 2012 [16] EDCC15±12India1993∼ 199846 095 42∼8162(0.13%)Suspected (62) Confirmed (36)S. Epidermidis(16); P. Aeruginosa(5); GPC (other)# (8) Others(7)OR: Ambulatory patients care (3.63) Residence location within city(2.27)ECCE PhacoemulsificationB
Keay L, 2012 [17] ? EDRONRUSA2003∼ 20043 280 966 NA4 006 (0.012%)Suspected (4006)NRRR: Male (1.23) Older individuals(≥85)(1.53) Black (1.17) Native Americans (1.72) Surgeons with low annual volume (3.8) Surgeons with less experience (1.41) surgeries performed in 2003 (1.2)NAB
Romero-Aroca P, 2012 [18] ? EDPO5.37±2.33Spain1996∼ 200925 001 53∼8983 (3.32%)Suspected (83) Confirmed (55)NRRR: Without intracameral cefazolin (11.45)PhacoemulsificationA
Tan CS, 2012 [19] ? EDCohNRSingapore11 years50 177 NR21(0.042%)Suspected(21)NROR: Without intracameral cefazolin (13.6) Age(1.05) Male gender(2.96)NAB
García-Sáenz MC 2010 [20] ? EDCSNRSpain1999∼ 200915 173 NR43(0.28%)Suspected (43)NRRR: Without intracameral cefuroxime (8.57)NAA
Anijeet DR, 2010 [21] EDRO1∼14UK1998∼ 200816 606 NR14(0.078%)Suspected(14) Confirmed(6)GPC#(1); P. Streptococcus(3) P. aeruginosa (1); Nil(1)RR: without intracameral vancomycin (38)NAB
Freeman EE 2010 [22] ? EDRO<90Canada1996∼ 2005490 690 NR754(0.15%)Suspected(754)NROR:Older individuals(≥85)(1.34) Male gender(1.44) later year of surgery (0.94) Region of surgery 6 and 9(6∼9)NAB
Lloyd JC, 2009 [23] EDRO1∼35Canada2006∼ 200513 931 NR5(0.036%)Suspected(5) Confirmed(4)Staphylococcus(2); Streptococcus(1);P.acnes(1);OR:Without fourth-generation fluoroquinolones perioperatively(6.3)PhacoemulsificationB
Al-Mezaine HS, 2009 [25] ? EDRONRArabia1029 412 NR20(0.068%)Suspected(20) Confirmed(18)Staphylococcus (7); Streptococcus(7); P.acnes(1); others(3)OR:clear corneal incision(1.73)ECCE PhacoemulsificationB
Garat M, 2009 [26] ? EDCCNRSpain2002∼ 200718 579 NR31(0.167%)Suspected(27) Confirmed(4)NRRR: Without intracameral cefazolin(8.89)PhacoemulsificationB
Hatch WV, 2009 [27] ? EDCohNRCanada2002∼ 2006442 177 NR617(0.14%)Suspected(617)NROR: Male gender(1.4) Capsular rupture(9.56) Older individuals(1.24)ECCE PhacoemulsificationA
Pleyer U, 2008 [28] ? EDCohNREuropeNR16211 NR29(0.179%)Suspected(29) Confirmed(20)NRRR: Without intracameral cefuroxime(4.92) Clear corneal incision(5.88) Silicon based IOL(3.13) Intraoperative complications(4.95)PhacoemulsificationA
Garcia-Arumi J, 2007 [30] ? EDCC<30Spain2002∼ 20035 011 NR27(0.539%)NRNROR: Topical anesthesia(11.8) Surgery longer than 45minutes(7.2)NAA
Endophthalmitis Study Group, 2007 [31] ? EDCohNRAustria, Belgium, Germany, Italy, etc.NR16 603 NR29(0.175%)Suspected(29) Confirmed(20)NROR: Without intracameral cefuroxime (4.92) Clear corneal incision(5.88) Silicone IOL(3.13) Surgical complications(4.95) Male gender(2.70)ECCE PhacoemulsificationA
Lundström M 2007 [32] ? EDPONRSweden2002∼ 2004225 471 NR109(0.048%)Suspected(109)NRRR: Communication between the anterior and vitreous Older individuals (≥85) Without intracameral cefuroximeECCE PhacoemulsificationA
Ng JQ, 2007 [33] ? WCCNRAustralia1980∼ 20001 025 NR205(NA)Suspected (205)NRRR: Same day surgery (2.27) Posterior capsule breach(13.57) Sub-conjunctival injection(0.46)ECCE PhacoemulsificationB
Kamalarajah S, 2006 [34] ? EDCCNRUK1999∼ 2000659 (73.5–75)214(NA)Suspected (214)NROR: Inpatient surgery(2.88) Dedicated center(2.76) Face masks not worn(3.34) Posterior capsule tear(3.82) Without subconjunctival antibiotics (6.85)ECCE PhacoemulsificationA
Barry P, 2006 [35] ? EDCohNRAustria, Belgium, Germany, Italy, etc.2003∼ 200613 698 NR28(0.2%)Suspected (28)NROR: Without intracameral cefuroxime (4.59)PhacoemulsificationA
Wu PC, 2006 [36] EDCCNRTaiwan1992∼ 200010 614 NR12(0.113%)Suspected (12)NROR: skin preparation with 5% povidone-iodine(10.9) without 5% povidone-iodine conjunctival disinfection(5.6)ECCEB
Wejde G, 2005 [37] ? EDCCNRSweden1994∼ 200044 986 NR60(0.133%)Suspected(60)NRRR: without intracameral cefuroxime(5.7) ECCE/ICCE(2.1) silicone lens((3.4)ECCE PhacoemulsificationB
Lalitha P, 2005 [38] ? EDRONRIndia2002∼ 200336 072 NR19(0.053%)Suspected(10) Confirmed(9)NRRR: posterior capsular rent(6.57) ECCE(4.9) older individuals(6.0)ECCE PhacoemulsificationB
West ES, 2005 [39] ? EDRONRUSA1994∼ 2001477 627 NR1 026(0.215%)Suspected(10) Confirmed(9)NRRR: surgeries before 1998(1.44) old individuals(90)(1.83) black race(1.30)ECCE PhacoemulsificationA
Wallin T, 2005 [40] ? EDCohNRUSA1996∼ 20021552 NR27(1.7%)Suspected(27)NRRR: Wound leak(44) Capsular complication(17.2) Topical antibiotic after surgery(13.7) With ciprofloxacin (5.3) Without patching (7.1) Without collagen shield (2.7)ECCE PhacoemulsificationB
Wejde G, 2005 [41] ? EDPONRSweden1999∼ 2001188 151 NR109(0.0595%)Suspected (91) Confirmed (21)GPB# RR: Without intracameral cefuroxime (3.649) ECCE/ICCE (1.7)ECCE PhacoemulsificationA
Li J, 2004 [42] ? WPONRAustralia1980∼ 2000117 083 NR210(0.179%)Suspected (210)NROR: Male 0.89(0.67–1.19) Older individuals(>80)1.50(1.13–1.99) Length of stay(+8days) (2.08) Private hospital (2.38) Length of study (>8days)(2.08) With vitreoretinal procedure (2.71) Lacrimal/eyelid procedures (23.5)ECCE ICCE Phacoemulsification other cataract extraction/ lens-related proceduresA
Wong TY, 2004 [43] ? EDPONRSingapore1996∼ 200144 803 NR34(0.076%)Suspected (34) Confirmed (21)RR:Phacoemulsification (3.1) Posterior capsule rupture (8.0)ECCE PhacoemulsificationA
Wong TY, 2004 [44] ? EDCC54∼80Singapore Chinese, Malay,etc.1996∼ 2001136 NR34(NA)Suspected (34) Confirmed (21)Staphylococcus (13) Streptococci (1); P.aeroginosa(1) Others(6)OR: Silicone IOL (5.1) Posterior capsular rupture (20.9)ECCE PhacoemulsificationB
Cooper BA, 2003 [45] ? EDCCNRUSA1997∼ 2000409 NR38(NA)Confirmed(38)NROR: Clear corneal incision (3.36)ECCE PhacoemulsificationB
E Mayer, 2003 [46] ? EDRONRUK1991∼ 200118 191 (43–89)30(0.16%)Suspected (30) Confirmed (26)Staphylococcus (9) P. Streptococcus (2) P.aeruginosa (1) Others(14)RR: ECCE (4.37) Folded IOL (43.8) Capsular rupture (2.06)ECCE PhacoemulsificationB
Ellis MF, 2003 [47] ? EDRONRAustralia1997∼ 2001633 NR5(0.78%)Confirmed (5)S. epidermidis (5)OR: Topical anesthesia (7.63)PhacoemulsificationB
Nagaki Y, 2003 [48] ? EDPONRJapan1998∼ 200111595 NR16(0.14%)Suspected (16) Confirmed (13)NRRR: Clear corneal incision (5.61)PhacoemulsificationA
Kalpadakis P, 2002 [49] ? EDRONRGreece1998∼ 20012 446 NR20(0.82%)Suspected (20)NRRR: ECCE (1.99)ECCE PhacoemulsificationA
Montan P, 2002 [50] ? EDPONRSweden199854 666 NR58(0.106%)Suspected (58) Confirmed (41)CNS #(15) Streptococci (12) S. aureus(4)OR: PMMA (2.03) Silicon (1.93) Hydrogel (2.89)Phaco + PC IOL ECCE + PC IOL Phaco/ECCE + AC IOLA
Lertsumitkul S, 2001[51] ? WCCNRAustralia1996∼ 199897 NR31(NA)Suspected (31) Confirmed (20)S. Epidermidis(9) S. aureus(5) Streptococcus(2)OR: Surgical complications (6.34) Clear corneal temporal incision (3.52)ECCE Phacoemulsification Penetrating keratoplastyB
Colleaux KM, 2000 [52] EDRONRSask1994∼ 199813 886 NR25 (0.18%)Suspected (25)NROR: without subconjunctival antibiotic injections (16.23)PhacoemulsificationB
Swaddiwudhipong W, 2000 [53] ? EDRONRThailand1997∼ 1998329 NR31(9.4%)Suspected (31)NRRR: ECCE (0.47)Phacoemulsification145 ECCE165 secondary IOL implantationB
Schmitz S, 1999 [54] EDCSNRGermany1996340 633 NR267 (0.148%)NRNROR: preoperative topical antibiotics (2.38) outpatient surgeries (2.0)NAA
Bainbridge JW, 1998 [55] ? EDRO12∼101United KingdomNA772 NR7(0.91%)Suspected (7) Confirmed(5)CNS# (3) S. aureus(1)RR: Silicone IOL (20.73)PhacoemulsificationB
Norregaard JC, 1997 [56] ? EDRONRDenmark1985∼ 198719 246 NR61(0.317%)Suspected (61)NROR: Old individuals≥90 (3.62) Male gender (1.93) ICCE (2.22) Capsular rupture (4.86)ECCE ± IOL ICCE ± IOLB
Javitt JC, 1991 [57] ? EDRONRUSA1984324 032 NR439(0.135%)Suspected(439)NROR: Capsular rupture (4.56) Male gender (1.23)ICCE 99971 ECCE 195587 Phacoemulsification 28474B

Note: ED, electronic database; W, Internet search; CC, case-control; Coh, cohort; CS, cross-sectional; RO, retrospective observational; PO, prospective observational; PK, Penetrating keratoplasty; ECCE, extracapsular cataract extraction; ICCE, intracapsular extraction; AC IOL: anterior chamber intraocular lens; PC IOL: posterior chamber intraocular lens; NA, not available; NR, not recorded; N, domain not addressed. *Results were put into meta-analysis & OR/RR with 95% confidence interval is for all suspected endophthalmitis cases, not limited the confirmed (culture-positive) endophthalmitis. # GPC: Gram-positive cocci other than S. epidermidis. GNB: Gram-negative bacilli other than P. aeruginosa. GPB: Gram-positive bacilli other than P. Acnes. CNS*: Coagulase negative staphylococci; ?The quality criteria: A  =  consistent level 1 studies (1a-c), B  =  consistent level 2 or 3 studies or extrapolations from level 1 studies(2a–c,3a–b) 1a,SR (with homogeneity) of RCTs; 1b: Individual RCT (with narrow Confidence Interval);1c: all or none; 2a: SR (with homogeneity) of cohort studies;2b: Individual cohort study (including low quality RCT; e.g., <80% follow-up);2c: “Outcomes” Research; Ecological studies;3a: SR (with homogeneity*) of case-control studies;3b: Individual Case-Control Study. All the included studies have no conflict of Interest.

Note: ED, electronic database; W, Internet search; CC, case-control; Coh, cohort; CS, cross-sectional; RO, retrospective observational; PO, prospective observational; PK, Penetrating keratoplasty; ECCE, extracapsular cataract extraction; ICCE, intracapsular extraction; AC IOL: anterior chamber intraocular lens; PC IOL: posterior chamber intraocular lens; NA, not available; NR, not recorded; N, domain not addressed. *Results were put into meta-analysis & OR/RR with 95% confidence interval is for all suspected endophthalmitis cases, not limited the confirmed (culture-positive) endophthalmitis. # GPC: Gram-positive cocci other than S. epidermidis. GNB: Gram-negative bacilli other than P. aeruginosa. GPB: Gram-positive bacilli other than P. Acnes. CNS*: Coagulase negative staphylococci; ?The quality criteria: A  =  consistent level 1 studies (1a-c), B  =  consistent level 2 or 3 studies or extrapolations from level 1 studies(2a–c,3a–b) 1a,SR (with homogeneity) of RCTs; 1b: Individual RCT (with narrow Confidence Interval);1c: all or none; 2a: SR (with homogeneity) of cohort studies;2b: Individual cohort study (including low quality RCT; e.g., <80% follow-up);2c: “Outcomes” Research; Ecological studies;3a: SR (with homogeneity*) of case-control studies;3b: Individual Case-Control Study. All the included studies have no conflict of Interest.

Statistical Analysis

The fully adjusted, study-specific ORs or RR were combined to estimate the pooled OR with 95% CI using the random effects model. RR was treated as ORs without further adjustment as the incidence of acute endophthalmitis in the studied populations was low (ie, <10%) [77]. Most of the studies included in our meta-analysis reported both an OR for any risk factor and ORs after stratification (Table 3). The random effects model was chosen because it accounts for both within-study and between-study variability. As our expect lies on testing for eventual differences between coefficients for the random effects model and the fixed effects model, we use a generalized Hausman specification test. The advantage of such specification test is that it makes use of the sandwich covariance estimator to adjust for any heteroskedasticity in the outcomes. For comparative purposes, we followed the same model for estimating the summary results of each factor.
Table 3

Summary results from the meta-analysis.

Risk factorProspectiveCross sectionalRetrospective
nPooled odds rationOverall estimatennOverall estimate
Male gender61.41(1.22∼1.63)12.70(1.07∼6.80)0NA51.38(1.21∼1.58)
Older individuals (≥85 years)71.50(1.18∼1.91)0NA0NA71.50(1.18∼1.91)
Without intracameral cefazolin310.76(6.45∼17.95)111.45(5.73∼22.88)0NA29.97(4.66∼21.33)
Without intracameral cefuroxime65.48(3.79∼7.92)44.09(2.86∼5.84)18.55(6.21∼11.76)15.70(2.77∼11.75)
Posterior capsular rupture106.34(4.23∼9.52)13.82(1.67∼8.72)0NA96.82(4.41∼10.55)
Clear corneal incision63.60(2.05∼6.31)35.65(3.75∼8.52)0NA32.44(1.46∼4.09)
Silicone based IOL63.02(2.03∼4.49)32.35(1.67∼3.30)0NA34.64(2.25∼9.56)
Intraoperative complications35.29(2.73∼10.18)24.95(2.31∼10.63)0NA16.34(1.77∼22.67)
ECCE/ICCE62.19(1.40∼3.24)0NA0NA62.19(1.40∼3.24)

n  =  number of estimates entered in the models; NA: not available.

Funnel plots were reviewed for each risk factors and no evidence of publication bias was observed.

n  =  number of estimates entered in the models; NA: not available. Funnel plots were reviewed for each risk factors and no evidence of publication bias was observed. Statistical heterogeneity among studies was evaluated using I2 Statistic. I2 is the percentage of the total variation across the studies that is due to heterogeneity [13]. Values of ≤24%, 25% to 49%, 50% to 74%, and >75% denote no, low, moderate, and high heterogeneity, respectively [14]. Heterogeneity due to study design was avoided by restricting the main analyses to the same study design respectively. Furthermore, we performed a sensitivity analysis that investigates the contribution of each study to the heterogeneity by sequentially omitting one study and reanalyzing the pooled estimate for the remaining studies [15]. Publication bias was evaluated with the use of Egger regression asymmetry test and the Begg's test. All statistical analyses were performed with Stata version 11.1 (StataCorp, College Station, TX). A 2-sided P value less than 0.05 was regarded as significant for all analyses.

Results

In total, data from 10 prospective studies [18], [28], [31]–[32], [34]–[35], [41], [43], [48], [50], 2 cross-sectional studies [20], [54] and 30 retrospective studies [16 ∼ 17, 19, 21 ∼ 27, 29 ∼ 30, 33, 36 ∼ 40, 42, 44 ∼ 47, 49, 51 ∼ 53, 55 ∼ 57] were included in the final analysis, contributing a sample of some 6 686 169 patients including 8 963 endophthalmitis cases. Table 2 summarizes the characteristics of the concluded studies from which estimates were included in the meta-analysis. Funnel plots were reviewed for each risk factors and no evidence of publication bias was observed. The findings for each risk factor were summarized in Table 3 and discussed separately in the following sections.

Age

All studies found a strong association with older individuals (≥85 years) (Figure 2) [17, 19 , 22, 27, 38∼39, 42, 56].
Figure 2

Pooled odds ratio for acute endophthalmitis and by age (≥85 years vs.<85 years).

Male gender

Six estimates from retrospective studies [17], [19], [22], [27], [56], [57] , and one prospective studies [31] contributed to this meta-analysis. Findings from this analysis suggest that there is a significant association between male gender and acute endophthalmitis. In the retrospective studies, the overall OR for male gender was 1.43 (95% CI 1.29 ∼ 1.58) , in the whole studies, it was 1.44 (95% CI 1.30 ∼ 1. 59) (Figure 3).
Figure 3

Pooled odds ratio for acute endophthalmitis by gender (male vs. female).

Extra- or intracapsular cataract extraction (ECCE / ICCE)

Six retrospective studies were included in the meta-analysis [37∼38, 46, 49, 53, 56]. Findings from the meta-analysis show an significant association between extra- or intracapsular cataract extraction and acute endophthalmitis (OR 2.19, 95% CI 1.40∼3.42) compared with phacoemulsification (Figure 4). Sensitivity analysis showed that the Swaddiwudhi pong W study [53] substantially influenced the pooled OR. After excluding this studies, the pooled OR was 2.37 (95% CI, 1.77∼3.17) with no evidence of heterogeneity (I2 = 0%; P = 0.41).
Figure 4

Pooled odds ratio for acute endophthalmitis by extra- or intracapsular cataract extraction (vs. phacoemulsification).

A clear corneal incision

Estimates from three prospective cohort studies ( i.e., Pleyer U, Endophthalmitis Study Group, and Nagaki Y) [28], [31], [48] and from three retrospective studies (Al-Mezaine HS, Cooper BA, Lertsumitkol S) [25], [45], [51], were analyzed. Analysis of the prospective cohort studies showed that a clear corneal incision is a strong risk factor for acute endophthalmitis (OR 5.65, 95% CI 3.75∼8.52). This finding is supported by the results of the meta-analysis of the retrospective studies (OR 2.44, 95% CI 1.46∼4.09) (Figure 5).
Figure 5

Pooled odds ratio for acute endophthalmitis by a clear corneal incision (vs. sclerocorneal incision or scleral tunnel incision).

Without intracameral cefazolin (1 mg in 0.1 ml solution)

Estimates were reported from one prospective cohort studies [18] and two case retrospective studies [19], [26] contributed to the meta-analysis. Significant increases in acute endophthalmitis risk were seen in all the meta-analyses for without intracameral cefazolin during cataract surgery procedure. The OR for prospective studies was 11.45 (95% CI 5.72∼22.84), and that from retrospective studies was 9.97 (95% CI 4.66∼21.33). The OR obtained through analysis of the whole studies was 10.76 (95% CI 6.45∼17.94) (Figure 6).
Figure 6

Pooled odds ratio for acute endophthalmitis by without intracameral cefazolin.

Without intracameral cefuroxime (1 mg in 0.1 ml solution)

Data from four prospective cohort studies [28], [31], [35], [41], one retrospective studies [37] and a pooled estimate from a cross sectional study [20] were used in the meta-analysis. The meta-analysis of the prospective cohort and retrospective studies suggests that intracameral cefuroxime is the protective effect against acute endophthalmitis compared with topical anti-infectives alone (OR 4.09, 95% CI 2.86∼5.84 , OR 5.70, 95% CI 2.76∼11.75 respectively). The overall OR with the cross sectional study supported this finding (OR 5.48, 95% CI 3.79∼7.92) (Figure 7).
Figure 7

Pooled odds ratio for acute endophthalmitis by without intracameral cefuroxime.

Posterior capsular rupture (PCR)

Eight retrospective studies [27, 33, 38, 40, 44, 46, 56∼57] and two prospective studies [34], [43] contributed to the meta-analysis. Analysis of the retrospective studies showed PCR, a common complication of cataract surgery, was also a significant risk factor of acute endophthalmitis (OR 6.33, 95% CI 4.22∼9.49). Prospective study findings were in the same direction (OR 6.75, 95% CI 3.31∼13.76) (Figure 8).
Figure 8

Pooled odds ratio for acute endophthalmitis by posterior capsular rupture.

Silicone IOLs

Estimates from three prospective cohort studies [28], [31], [50] and from three retrospective studies [37], [44], [55] contributed to this analysis. Both of the analyses showed statistically significant associations (prospective cohort studies OR 2.35, 95% CI 1.67∼3.30; retrospective studies OR 4.64, 95% CI: 2.25∼9.56). The whole studies did identify a significant association between silicone intraocular lens and acute endophthalmitis (OR 3.02, 95% CI 2.03∼4.49) (Figure 9).
Figure 9

Pooled odds ratio for acute endophthalmitis by silicone based IOLs (compared with PMMA or acrylic IOLs).

Intraoperative complications

A significant increase in risk of acute endophthalmitis with intraoperative complications in two prospective studies [28 ∼ 31], (OR 4.95, 95% CI 2.31∼10.63). There was only one estimate from a retrospective study [51] and it also supported this finding (OR 6.34, 95% CI 1.77∼22.67) of significance (Figure 10).
Figure 10

Pooled odds ratio for acute endophthalmitis by intraoperative complications.

Discussion

Identifying patients at high risk of acute endophthalmitis after cataract surgery is important from both public health and clinical perspectives as this would facilitate detection of disease before the onset of irreversible visual loss enabling earlier intervention. Of the nine risk factors identified in our systematic review and meta-analysis, ECCE / ICCE, a clear corneal incision, without intracameral cefazolin (1 mg in 0.1 ml solution) , without intracameral cefuroxime (1 mg in 0.1 ml solution), PCR, silicone intraocular lens and intraoperative complications were strongly and consistently associated with acute endophthalmiytis. All of these are easily assessed through discussions with patients and do not entail a lengthy medical history taking or laboratory evaluations. Other significant factors with a lower strength of association (risk estimates generally 1.5 or less) were male gender and old individuals (85 years and older). All of these factors are likely to be measured and monitored in the primary care setting. As we and others have previously reported, we found that patient factors such as older age and male gender are associated with a higher risk of endophthalmitis after cataract surgery. The increased risk with age was only true for the very old ages (85 years) and this result might be explained by a reduced natural immunity in this advanced age group [22], [32], [42]. Several studies have reported increased rates of adverse postsurgical events among men [22], [31]. Using the analysis data, researchers noted that men had 41% higher odds of postoperative endophthalmitis, compared with women. Possible explanations for the higher complication rates in male patients include behavioral differences (e.g., adherence to postoperative instructions and antibiotic use) [58]; differences in bacterial flora between the genders [59]; and use of a-antagonists, which can increase the surgical complexity, as they can lead to intraoperative floppy iris syndrome [24]. Although small-incision phacoemulsification has remained the standard of care, surgeons continue to debate whether modifications in surgical technique have affected complication rates. Our pooled analysis of six studies confirmed the increased risks of acute POE associated with ECCE/ICCE compared with phacoemulsification surgery from both developed and developing countries. It was consistent with the reports of western Australia in 2011 [60] and southern India in 2009 [61]. While other studies have found on difference [62 ∼ 64] or the opposite conclusion [43] comparing postoperative complication rates with the transition from ECCE to phacoemulsification techniques. In a setting with phacoemulsification as the standard method, a selection bias for ECCE/ICCE in particularly difficult cases, e.g. instrumental surgical intervention for mature and hypermature cataracts is possible to lead to some complications concerning zonular fiber damaging, is introduced that may very well influence the results. The larger incision and the longer duration of the operation in ECCE than in phacoemulsification, together with the use of perioperative intracameral antibiotics in the phacoemulsification operation may explain this difference. Is a clear corneal incision associated with greater odds of endophthalmitis compared with a scleral tunnel or limbal incision? Controversy exists regarding the problem. Theories to account for more frequent POE with sutureless clear corneal incisions are centered on the stability of the surgical wound because its integrity is believed to be a critical factor. A stable, self-sealing incision may be technically more difficult in the cornea than in the sclera. Many reports concluded that postoperative wound defects were a risk factor for the development of endophthalmitis [65], [66] and the corneal incision at least 2.0mm in length had substantially greater resistance to incision failure [45]. This suggests that the integrity of a self-sealing incision depends to some extent on length. This may be more difficult in a clear corneal incision. If the incision is too short, the cataract wound may be susceptible to a postoperative perturbation (such as rubbing of the eye) and wound abnormality. According to the innovations in phacoemulsification technology, the types of instruments available to better manage complex cases (pupil stretchers, capsular tension rings, dyes to stain the capsule), increased use of topical anesthesia, improvements in intraocular lenses, changes in preoperative or postoperative medication regimens, and better strategies to deal with intraoperative complications, two more recent studies showed the rates of adverse events, including endophthalmitis, decreased among patients undergoing small-incision phacoemulsification from 1994 to 2006 [22], [67]. The incision location, structure and length should be more thoroughly studied in large prospective trials in the future. Three multicenter prospective randomized partially masked control study concurred that the most pertinent finding of the protective effect against infection produced by the prophylactic use of intracameral cefuroxime (1 mg in 0.1 ml solution) compared with topical disinfection alone [28], [31], [35]. A current prospective observational study reported the intracameral cefazolin (1 mg in 0.1 ml solution) significantly reduced the rate of postoperative endophthalmitis. The magnitude of the ORs shown by our meta-analysis were inconsistent across studies while the pooled estimates were statistically significant for both without intracameral cefuroxime (OR 5.48, 95% CI 3.79∼7.92) and without intracameral cefazolin (OR 10.76, 95% CI 6.45∼17.95) with no evidence of heterogeneity (I2 = 48.6%, P = 0.083; I2 = 0%, P = 0.858 respectively). Coagulase-negative staphylococcus (shown in Table 2) is the most commonly isolated organism and is followed by other gram-positive organisms (such as staphylococcus aureus, streptococcus species) and gram-negative bacteria. Cefuroxime or cefazolin is usually effective against the broad spectrum of bacteria causing acute onset postoperative endophthalmitis. Endophthalmitis caused by coagulase-negative staphylococci may have less inflammatory signs, often creating difficulty in distinguishing between an infective and a noninfective etiology. Many surgeons fear an increased incidence of toxic anterior segment syndrome (TASS) with injected antibiotics, such as the toxic effects of higher concentrations of cefuroxime and vancomycin on human corneal endothelial cells [70]. More research on the clinically used concentrations was recommended. Our meta-analysis confirmed the increased risks of acute endophthalmitis associated with silicone lOLs. This seems to corroborate experimental studies [55], [68], [69] and also some clinical data, reporting an increased bacterial adhesion to silicone lenses compared with polymethylmethacrylate lOLs and hydrophobic acrylic IOLs, as the first-line implants in most operating practice due to the favoring of foldable IOLs to avoid induction of astigmatism [74∼76]. The future new lens materials or design may confer greater resistance of intraocular organisms to physiological and pharmacological antibacterial protective mechanisms. Evaluation on the uveal and capsular biocompatibility shape of IOL should also be considered to prohibit lens epithelial cell migration and postoperative inflammation. Posterior capsular rupture caused intraoperative communication with the vitreous cavity, was found to be a significant risk factor for postoperative endophthalmitis, which was well proved by in vitro experiments [71] and animal models [72], [73]. Our pooled estimates revealed that PCR was associated with an increased risk of more than six-fold for acute endophthalmitis. This risk increased when we excluded the two studies that had a lower cut-off for prospective design. When other intraoperative complications were added, the pooled estimates OR was 5.28 (95% CI, 2.74∼10.18), suggesting that PCR may be the common intraoperative risk and do most contribution to the incidence of endophthalmitis. There are several strengths in our systematic review. We performed a comprehensive search through six databases, had inclusion criteria for the prospective, cross-sectional and retrospective studies. The fully adjusted study-specific ORs were combined to estimate the pooled ORs with 95% CI using the random effects model for analyze the heterogeneity. The uniquely large sample size and inclusion of studies from different ethnic populations around the world could provide a more precise estimate of the perioperative risk factors for POE in the general population because they included known, presumably symptomatic, and unknown risks. There are potential limitations to the present literature synthesis, some inherent to systematic reviews in general and some particular to our review. First, the studies included in this analysis may be subject to some methodological variation. Definitions of endophthalmitis may have varied; in addition, inherent difficulties in the diagnosis of this complication are apparent secondary to the uncommon manifestation of the “classic” form of postsurgical endophthalmitis. Miscoding of endophthalmitis itself could be a serious concern for data quality of any epidemiological analysis. Second, the overwhelming number of publications showing retrospective data, and the limited number of prospective and case-controlled studies with appropriate randomization methods, negatively affected the proportion of high-quality articles reviewed. Systematic reviews have an intrinsic limitation: the quality of the outcome depends on the quality of the inputs. Therefore, their findings must be interpreted with caution. Nonetheless, many studies included in this review were from Asian populations (e.g. Chinese, Malay Asians, Thailand, India) and thus, we believe our results can be generalizable to different populations in different countries around the world. Finally, the major setback of published studies and meta-analyses of published studies in general is publication bias. Publication bias may be an issue because studies that report statistically significant results are more likely to get published than studies that report nonsignificant results, and this could have distorted the findings of our meta-analyses. Therefore, potentially additional unpublished evidence regarding risk factors of acute endophthalmitis following cataract surgery during the past decade may be unavailable for analysis [4]. However, Egger regression asymmetry test and the Begg's test suggested no evidence of publication bias in our study. Nonetheless, even with these limitations in mind, we believe that our analysis provides clear evidence to support the notion that the nine risk factors for acute endophthalmitis. This study provides additional information for primary care physicians, general ophthalmologists and other eye care professionals to counsel their patients on acute POE risk. PRISMA Checklist. (DOC) Click here for additional data file.
  71 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.

Authors:  J Zhang; K F Yu
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

Review 3.  Endophthalmitis prophylaxis.

Authors:  Judy I Ou; Christopher N Ta
Journal:  Ophthalmol Clin North Am       Date:  2006-12

4.  Risk factors for endophthalmitis following cataract surgery: a retrospective case-control study.

Authors:  G Wejde; B Samolov; S Seregard; G Koranyi; P G Montan
Journal:  J Hosp Infect       Date:  2005-11       Impact factor: 3.926

Review 5.  Prevention of postcataract endophthalmitis: evidence-based medicine.

Authors:  Charles Q Yu; Christopher N Ta
Journal:  Curr Opin Ophthalmol       Date:  2012-01       Impact factor: 3.761

6.  Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes.

Authors:  T M Aaberg; H W Flynn; J Schiffman; J Newton
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

7.  Intracameral vancomycin following cataract surgery: An eleven-year study.

Authors:  Deepa R Anijeet; Prasad Palimar; Clive O Peckar
Journal:  Clin Ophthalmol       Date:  2010-04-26

8.  Incidence of postoperative endophthalmitis in a high-volume cataract surgicentre in Canada.

Authors:  John C Lloyd; Rosa Braga-Mele
Journal:  Can J Ophthalmol       Date:  2009-06       Impact factor: 1.882

9.  Risk factors of acute endophthalmitis after cataract extraction: a case-control study in Asian eyes.

Authors:  T Y Wong; S-P Chee
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

10.  Variation in cataract surgery practice and clinical outcomes.

Authors:  O D Schein; E P Steinberg; J C Javitt; S D Cassard; J M Tielsch; D M Steinwachs; M W Legro; M Diener-West; A Sommer
Journal:  Ophthalmology       Date:  1994-06       Impact factor: 12.079

View more
  41 in total

1.  Predictive modeling of risk factors and complications of cataract surgery.

Authors:  Gregory L Gaskin; Suzann Pershing; Tyler S Cole; Nigam H Shah
Journal:  Eur J Ophthalmol       Date:  2015-12-17       Impact factor: 2.597

2.  Risk factors for endophthalmitis following cataract surgery-our experience at a tertiary eye care centre in India.

Authors:  Rohit C Khanna; Vanita Pathak Ray; Madhavi Latha; Sandra D Cassard; Annie Mathai; Garudadri C Sekhar
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

Review 3.  Risk of Fungal Endophthalmitis Associated with Cataract Surgery: A Mini-Review.

Authors:  Tonya C Smith; Russell J Benefield; Jong Hun Kim
Journal:  Mycopathologia       Date:  2015-08-29       Impact factor: 2.574

4.  Identification and Description of Reliable Evidence for 2016 American Academy of Ophthalmology Preferred Practice Pattern Guidelines for Cataract in the Adult Eye.

Authors:  Asieh Golozar; Yujiang Chen; Kristina Lindsley; Benjamin Rouse; David C Musch; Flora Lum; Barbara S Hawkins; Tianjing Li
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

Review 5.  Endophthalmitis: Then and Now.

Authors:  Nidhi Relhan; Richard K Forster; Harry W Flynn
Journal:  Am J Ophthalmol       Date:  2017-12-05       Impact factor: 5.258

6.  Intracameral Antibiotics in the Shadow of Hemorrhagic Occlusive Retinal Vasculitis.

Authors:  Ayman Naseri; Ronald B Melles; Neal H Shorstein
Journal:  Ophthalmology       Date:  2017-05       Impact factor: 12.079

Review 7.  Intraoperative floppy iris syndrome: an updated review of literature.

Authors:  Amit Kumar; Amit Raj
Journal:  Int Ophthalmol       Date:  2021-06-29       Impact factor: 2.031

Review 8.  Ocular Infection: Endophthalmitis.

Authors:  Stephen G Schwartz; Harry W Flynn; Taraprasad Das; William F Mieler
Journal:  Dev Ophthalmol       Date:  2015-10-26

9.  The Malaysian cataract surgery registry: incidence and risk factors of postoperative infectious endophthalmitis over a 7-year period.

Authors:  Yong Zheng Wai; Lee Min Fiona Chew; Aziz Salowi Mohamad; Chai Liang Ang; Yong Yuin Chong; Tassha Hilda Adnan; Pik-Pin Goh
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

10.  Effectiveness of 0.66% Povidone-Iodine Eye Drops on Ocular Surface Flora before Cataract Surgery: A Nationwide Microbiological Study.

Authors:  Rosario Musumeci; Pasquale Troiano; Marianna Martinelli; Matteo Piovella; Claudio Carbonara; Scipione Rossi; Giovanni Alessio; Luisa Molteni; Claudio Giuseppe Molteni; Laura Saderi; Giovanni Sotgiu; Clementina Elvezia Cocuzza
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.